Hyperkalemia treatment follows a layered strategy: protect the heart first, shift potassium out of the bloodstream temporarily, then remove the excess from the body for good. The urgency and combination of these steps depends on how high the potassium level is and whether the heart’s electrical activity is already affected. What looks straightforward on paper, though, gets complicated fast by drug interactions, unreliable lab values, and some surprisingly outdated practices still in use.
Why Potassium Levels Matter So Much
Almost all the potassium in your body sits inside your cells, not in your blood. The kidneys handle long-term balance by adjusting how much potassium gets excreted in urine, responding to shifts in dietary intake and hormonal signals.1PubMed Central. Regulation of Potassium Homeostasis The small amount of potassium circulating in your blood is tightly regulated because even modest increases can change how your heart muscle conducts electricity. When serum potassium climbs above roughly 5.0 to 5.5 mmol/L, you’ve entered hyperkalemia territory. Mild cases may cause no symptoms at all, but severe cases can cause fatal cardiac arrest without warning.
What makes hyperkalemia dangerous isn’t just the absolute number. The speed of the rise matters too. A patient whose potassium has crept up slowly over weeks may tolerate a level that would be immediately life-threatening if it spiked over a few hours. That’s why treatment decisions rely on both the lab value and the clinical picture, especially the electrocardiogram.
Check the Lab Value Twice
Before treating, clinicians need to confirm the reading is real. Pseudohyperkalemia, a falsely elevated potassium result caused by how the blood sample was collected or handled, is surprisingly common. Clenching the fist too hard during a blood draw, using a tourniquet for too long, or rough transport of the sample can rupture red blood cells and release their intracellular potassium into the tube. Patients with very high white blood cell counts or platelet counts are also prone to spurious results.2Nigerian Journal of Medicine. Pseudohyperkalemia Revisited: An Updated Review of a Foremost Preanalytical Error of Serum or Plasma Potassium Measurement in the Clinical Laboratory Treating a number that isn’t real wastes time and exposes the patient to unnecessary medications, including insulin-induced low blood sugar. When the clinical picture doesn’t match the lab result, repeating the draw with careful technique is the right first move.
Cardiac Protection With Calcium
When severe hyperkalemia is confirmed and the ECG shows worrisome changes, the first drug given is intravenous calcium, usually calcium gluconate or calcium chloride. Calcium does not lower potassium at all. Its job is to protect the heart while the potassium-lowering treatments take effect. ECG changes that signal danger include peaked T waves, a widening QRS complex, and flattening of the P wave.3PubMed Central. ECG frequency changes in potassium disorders: a narrative review In critically ill patients, the ECG is often the fastest way to gauge the severity of hyperkalemia, though the classic peaked T wave that most people learn about in textbooks is actually not a reliable marker for the most dangerous levels.4PubMed. Electrocardiographic manifestations of severe hyperkalemia
For decades, the explanation given for why calcium works was “membrane stabilization,” the idea that calcium restores the resting electrical potential of heart cells. Recent experimental work has challenged this. A 2024 study found that calcium treatment did not actually restore the resting membrane potential or the normal action potential duration in hyperkalemic cardiac tissue. Instead, calcium appeared to rescue conduction by enabling a calcium-dependent form of electrical propagation that bypasses the sodium channels that hyperkalemia impairs. Conduction velocity improved by about 44%, narrowing the QRS complex and normalizing the ECG, but through a mechanism distinct from the textbook explanation.5PubMed Central. Beneficial Effect of Calcium Treatment for Hyperkalemia Is Not Due to “Membrane Stabilization” The practical takeaway: calcium still works and should still be the first thing given in a cardiac emergency, but the reason it works is not what most clinicians were taught.
Shifting Potassium Into Cells
Calcium buys time; the next step is to move potassium from the blood into the body’s cells, which temporarily lowers the serum level. This doesn’t remove any potassium from the body. It parks it somewhere safer while definitive removal strategies get started. Two main drugs do this: insulin and inhaled beta-2 agonists.
Insulin With Glucose
Intravenous insulin is the workhorse of acute hyperkalemia treatment. It activates pumps on cell membranes that pull potassium inside. The standard dose is 10 units of short-acting insulin given intravenously, paired with enough glucose (around 25 to 50 grams) to prevent the blood sugar from crashing. For severe hyperkalemia above 6.5 mmol/L or with significant ECG changes, some protocols use 20 units infused over 60 minutes with 60 grams of glucose.6PLoS ONE. Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review
The biggest practical problem with insulin therapy is hypoglycemia. Real-world data from emergency departments show that roughly 12% of patients experience a low blood sugar event within the first hour after treatment, with additional events occurring over the following hours.7PubMed. Evaluation of Care Outcomes of Patients Receiving Hyperkalemia Treatment With Insulin in Acute Care Tertiary Hospital Emergency Department Patients with kidney disease, who make up the majority of severe hyperkalemia cases, are especially vulnerable because insulin is cleared more slowly when the kidneys aren’t working well. Frequent blood sugar monitoring for at least several hours after treatment is essential but sometimes gets dropped in busy emergency settings.
Inhaled Beta-2 Agonists
Nebulized albuterol (salbutamol in many countries) also drives potassium into cells by a different mechanism than insulin, which makes the two useful together. A dose of 10 to 20 mg delivered by nebulizer can lower potassium by about 0.6 to 1.0 mmol/L, with the effect appearing within 30 minutes and lasting at least two hours.8PubMed. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis A scoping review confirmed that the potassium-lowering effect of beta-2 agonists typically begins within 5 to 30 minutes and peaks between one and four hours, with some responsive patients seeing reductions over 1.6 mmol/L.9PLoS One. Utility of inhaled β2-agonists in reducing serum potassium levels in adult patients with hyperkalemia: A scoping review
The doses used here are much higher than what you’d take for asthma, which means side effects like a racing heartbeat and tremor are common. In patients with active cardiac ischemia, that can be a meaningful risk. Still, adding albuterol to insulin is reasonable in most situations because the two together produce a bigger drop than either alone.
The Bicarbonate Debate
Sodium bicarbonate was once a standard part of every hyperkalemia protocol. Its role has become contentious. A retrospective study of emergency department patients found that adding bicarbonate to insulin did not produce a statistically significant extra drop in potassium compared with insulin alone.10PubMed. Sodium bicarbonate administration and subsequent potassium concentration in hyperkalemia treatment Based on findings like this, many institutions have removed bicarbonate from their default hyperkalemia order sets.
Not everyone agrees this was the right call. A commentary in Kidney International Reports argued that the evidence against bicarbonate was being over-interpreted, and that in patients who are genuinely acidotic, hypertonic bicarbonate still has a role because correcting the acid-base disturbance itself helps move potassium into cells.11PubMed Central. Treatment of Severe Hyperkalemia: Confronting 4 Fallacies A review in Annals of Intensive Care similarly noted that hypertonic bicarbonate infusion remains an option in acidotic patients, though it carries the drawback of delivering a large sodium load.12PubMed Central. Management of hyperkalemia in the acutely ill patient The practical resolution: bicarbonate is probably not useful as a routine add-on for every hyperkalemia case, but abandoning it completely in patients with severe metabolic acidosis seems premature.
Actually Removing Potassium From the Body
Everything described so far is a temporizing measure. The potassium is still in the body; it’s just been shuffled around. To truly resolve hyperkalemia, you need to get the excess potassium out, either through the kidneys, the gut, or a dialysis machine.
Dialysis
In patients who already have end-stage kidney disease or whose kidneys simply cannot excrete potassium fast enough, hemodialysis is the most effective option. A multicenter observational study found that among all the treatments used in emergency departments, only dialysis reliably brought the median potassium level back to normal within four hours.13PubMed. Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): A Multicenter, Prospective, Observational Study The tradeoff is that dialysis requires vascular access, specialized equipment, and trained staff, making it less practical in some settings and completely unavailable outside of hospitals. For patients already on maintenance dialysis, the management strategy blends routine dialysis scheduling with dietary potassium restriction and avoidance of drugs that worsen the problem.14PubMed Central. Current Management of Hyperkalemia in Patients on Dialysis
The Old Potassium Binder and Its Problems
Sodium polystyrene sulfonate, known by its brand name Kayexalate, has been used since the 1950s. It works in the gut, exchanging sodium for potassium and carrying the potassium out in stool. For decades it was the only oral option for lowering potassium outside of dialysis. It has never been popular with patients (the taste and texture are unpleasant, and constipation is common), and its safety profile has drawn serious scrutiny.
A case series documented intestinal necrosis, sometimes fatal, occurring in patients who received SPS, with an overall mortality of 36% in that cohort.15PubMed Central. Intestinal Necrosis due to Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol The cases were associated with formulations that included sorbitol, which has since been removed from most preparations. A systematic review and meta-analysis of over 26,000 patients found a pooled odds ratio for intestinal necrosis of about 1.4 with SPS use, which was not statistically significant on its own, but the pooled estimate for serious gastrointestinal adverse events overall was significantly elevated.16PubMed. Risk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta-analysis A study of older adults found that SPS use roughly doubled the risk of hospitalization for a serious GI event within 30 days, with intestinal ischemia carrying the highest individual hazard.17JAMA Internal Medicine. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age The absolute risk is low, but these are severe, sometimes fatal events, and better alternatives now exist.
Newer Potassium Binders
Two newer oral potassium binders have changed the landscape for outpatient and subacute management. Patiromer (brand name Veltassa) is a polymer that exchanges calcium for potassium in the GI tract. It’s sodium-free, which matters for patients with heart failure or fluid retention. Clinical trials showed it effectively lowered potassium over weeks in patients with chronic kidney disease who were also taking blood pressure medications that raise potassium, and it allowed most of those patients to stay on their heart-protective drugs.18PubMed. Patiromer: A Review in Hyperkalaemia
Sodium zirconium cyclosilicate (brand name Lokelma) works by a different mechanism, trapping potassium in a crystal lattice in the gut. It acts faster than patiromer, with potassium reductions observed as early as one to four hours and drops of up to about 1.3 mmol/L within 48 hours.19Kidney and Dialysis. Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety Despite that speed, it is not currently approved for treating acute life-threatening hyperkalemia, so its primary role is in outpatient maintenance and subacute settings.20PubMed. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia
Both drugs are better tolerated than the old resin, and both have shifted the clinical conversation. The biggest practical impact has been enabling patients to stay on RAAS inhibitors, the class of blood pressure and heart failure drugs that are a leading cause of hyperkalemia in people with kidney disease. Historically, many patients had these protective medications discontinued or dose-reduced because of potassium concerns. The newer binders maintain normokalemia well enough that more patients can keep their RAAS inhibitors on board.21PubMed Central. Revisiting RAAS blockade in CKD with newer potassium-binding drugs
Medications That Cause the Problem
Drug-induced hyperkalemia is extremely common, and treatment sometimes means adjusting or stopping the offending medication rather than adding more drugs on top. The biggest culprits are the RAAS inhibitors: ACE inhibitors, angiotensin receptor blockers, and direct renin inhibitors. But the list extends well beyond that group. NSAIDs (common over-the-counter painkillers), calcineurin inhibitors used after organ transplants, heparin and related blood thinners, potassium-sparing diuretics, and the antibiotic trimethoprim can all impair the kidney’s ability to excrete potassium.22PubMed. Drug-induced hyperkalemia In many patients, it’s the combination of two or more of these drugs, sometimes prescribed by different doctors who aren’t coordinating, that tips potassium over the edge. A careful medication review is one of the simplest and most underused interventions in hyperkalemia management.
Rethinking the Low-Potassium Diet
If you have kidney disease, you’ve probably been told to avoid bananas, potatoes, and tomatoes. The standard advice to restrict dietary potassium has been a pillar of chronic kidney disease management for decades. But the evidence supporting strict potassium restriction is weaker than most patients realize, and there’s a growing argument that the traditional approach does more harm than good.
Fruits and vegetables are high in potassium, but they’re also the foundation of a heart-healthy diet. Patients with kidney disease are far more likely to die from cardiovascular causes than from a single episode of hyperkalemia, and a plant-based diet has been linked to better blood pressure, slower kidney disease progression, and lower stroke risk. Restricting produce to keep potassium numbers down may be solving one problem while worsening the bigger one.23PubMed Central. Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet
A literature review recommended a more individualized approach: identify hidden sources of potassium first (processed foods and preservatives are major contributors that often get overlooked), try techniques like soaking or boiling vegetables to reduce their potassium content, and introduce any restrictions gradually rather than imposing blanket bans on entire food groups.24PubMed Central. Moderate stepwise restriction of potassium intake to reduce risk of hyperkalemia in chronic kidney disease: A literature review The availability of the newer potassium binders adds another layer. If a daily binder can keep potassium in check, the dietary restrictions can be loosened, giving the patient access to the cardiovascular benefits of a more varied diet.
Fludrocortisone as a Niche Option
Most hyperkalemia treatment discussions focus on the acute setting or on potassium binders for chronic management. A less-discussed option exists for a specific subset of patients: fludrocortisone, a synthetic mineralocorticoid that tells the kidneys to excrete more potassium. It was first described for hyperkalemia management in patients with a condition called hyporeninemic hypoaldosteronism, where the hormonal signal to excrete potassium is deficient.25PubMed. Amelioration of metabolic acidosis with fludrocortisone therapy in hyporeninemic hypoaldosteronism
More recent data in pre-dialysis chronic kidney disease patients showed impressive results: potassium dropped from about 6.1-6.4 mmol/L to about 4.1-4.5 mmol/L after starting low-dose fludrocortisone, and the proportion of patients with dangerously high levels above 6.0 fell from nearly half to almost none.26PubMed Central. Use of Fludrocortisone for Hyperkalemia in Chronic Kidney Disease Not Yet on Dialysis The catch is sodium retention. Fludrocortisone makes the kidneys hold onto sodium and water, which can worsen fluid overload and raise blood pressure. For patients who already have heart failure or poorly controlled hypertension, that tradeoff rarely makes sense. But in the right patient, particularly someone with a documented aldosterone deficiency and stable fluid status, it can be a useful tool that avoids the need for daily binders.
Why Emergency Department Practices Still Vary So Much
Given how well the treatment algorithm is understood, you might expect every emergency department to handle hyperkalemia the same way. They don’t. A multicenter observational study found considerable variation in how emergency physicians treated hyperkalemia, from which drugs were used to the doses chosen to how often potassium was rechecked.27PubMed. Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): A Multicenter, Prospective, Observational Study Part of this reflects genuine clinical judgment: a mildly elevated potassium in a stable patient doesn’t need the same aggressive response as a level of 7.5 with a widening QRS. But part of it is institutional habit, outdated protocols, and the persistent use of treatments whose evidence base is shaky.
Hypoglycemia after insulin treatment is a good example of a predictable, preventable complication that still occurs at rates that would be considered unacceptable for most other emergency medications. Standardized order sets that pair insulin with an appropriate glucose dose, mandate blood sugar checks at one and two hours, and include a protocol for treating hypoglycemia if it occurs can reduce these events. Some hospitals have adopted such bundles; many have not. If you or a family member is being treated for hyperkalemia in an emergency setting, asking whether glucose monitoring is included in the plan is a reasonable and potentially important question.
Keeping RAAS Inhibitors on Board
One of the most consequential decisions in hyperkalemia management has nothing to do with the acute episode: it’s what happens to the patient’s long-term medications afterward. RAAS inhibitors like ACE inhibitors and ARBs are among the best-studied drugs in medicine for protecting the kidneys and heart in people with chronic kidney disease, diabetes, or heart failure. They also raise potassium. When a patient shows up with hyperkalemia, the reflexive response is often to stop the RAAS inhibitor permanently. That solves the potassium problem but removes a drug that was reducing the patient’s risk of kidney failure and cardiovascular death.
A trial published in the New England Journal of Medicine demonstrated that patiromer could keep potassium in the normal range in patients with kidney disease who were taking RAAS inhibitors, and that stopping patiromer led to a recurrence of hyperkalemia while the RAAS inhibitor was still on board.28PubMed. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors The clinical question that remains unanswered by randomized trials is whether using a binder to maintain RAAS inhibitor therapy ultimately translates to fewer heart attacks, less kidney failure progression, and longer survival compared with simply stopping the RAAS inhibitor.29PubMed Central. Revisiting RAAS blockade in CKD with newer potassium-binding drugs Most nephrologists believe the answer will be yes, based on the strong evidence behind RAAS inhibitors themselves, but the definitive outcome trials have not been completed.